GlassScriptPhysician profile
Thomas Leath
NPI 1497767420
$8,802.86
in general payments reported to CMS, 2019-2025
39 companies · $1,520 in 2025
The $1,520 reported for 2025 was more than what a typical Allergy & Immunology provider received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $638 · 2020: $888 · 2021: $1,379 · 2022: $1,153 · 2023: $1,534 · 2024: $1,691 · 2025: $1,520.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,677 · Education: $47.76 · Consulting Fee: $20.30.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,676.89 |
| Education | $47.76 |
| Consulting Fee | $20.30 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $2,024.37 | 2019-2025 | Fasenra, Tezspire, Airsupra |
| Glaxosmithkline, LLC. | $1,218.51 | 2019-2025 | Trelegy Ellipta, Nucala |
| Regeneron Healthcare Solutions, INC. | $821.64 | 2020-2025 | Dupixent |
| Takeda Pharmaceuticals U.S.A., INC. | $670.05 | 2020-2025 | Cuvitru, Takhzyro, Eohilia |
| Genzyme Corporation | $597.04 | 2019-2025 | |
| Csl Behring | $356.89 | 2019-2025 | Hizentra, Haegarda |
| Alk-Abello, INC | $315.74 | 2019-2025 | Grastek, Odactra, Ragwitek |
| Amgen INC. | $267.96 | 2021-2025 | Tezspire |
| Kaleo, INC. | $238.65 | 2019-2023 | Auvi-Q |
| Novartis Pharmaceuticals Corporation | $237.54 | 2019-2025 | |
| Biocryst US Sales Co., LLC | $207.54 | 2021-2022 | |
| Octapharma USA, INC. | $206.62 | 2021-2023 | Cutaquig |
| Pharming Healthcare, INC. | $192.24 | 2019-2025 | Ruconest |
| Leo Pharma INC. | $130.42 | 2024-2025 | Adbry |
| Grifols USA, LLC | $129.83 | 2021-2024 | Xembify |
Show all 39 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Leath listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.